Get startedLog in
    Picture of ImmuneOnco Biopharmaceuticals (Shanghai) logo

    1541 — ImmuneOnco Biopharmaceuticals (Shanghai) News Story

    0.000.00%
    hk flag iconLast trade - 00:00
    HealthcareHighly SpeculativeSmall CapSucker Stock
    All News

    Brief: Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody

    Picture of ImmuneOnco Biopharmaceuticals (Shanghai) logoImmuneOnco Biopharmaceuticals (Shanghai)
    14/01/2025 12:38
    Jan 14 (Reuters) - 
    Instil Bio  TIL.O :
    * INSTIL BIO ANNOUNCES CLINICAL PROGRESS IN CHINA FOR
IMM2510/SYN-2510, A CLINICAL-STAGE PD-L1XVEGF BISPECIFIC
ANTIBODY
    * INSTIL BIO INC - INITIAL CLINICAL DATA FROM 1L ADVANCED
NSCLC
TRIAL IN CHINA EXPECTED 2H 2025
    * INSTIL BIO INC - TARGETS INITIATION OF 1L ADVANCED NSCLC
TRIAL
IN 2H 2025
    * INSTIL BIO INC - PLANS U.S. TRIAL OF SYN-2510/IMM2510 IN
2H 2025

Source text:  ID:nGNX9t4VXy 
Further company coverage:  TIL.O 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on ImmuneOnco Biopharmaceuticals (Shanghai)

    See all news